Charles Schwab
GNMX

Charles Schwab’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Charles Schwab’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-44,012
Closed -$82K – 3171
2017
Q1 		$82K Hold
44,012
– – ﹤0.01% 3026
2016
Q4 		$228K Hold
44,012
– – ﹤0.01% 2932
2016
Q3 		$246K Hold
44,012
– – ﹤0.01% 2852
2016
Q2 		$245K Buy
44,012
+20,300
+86% +$107K ﹤0.01% 2864
2016
Q1 		$105K Hold
23,712
– – ﹤0.01% 2986
2015
Q4 		$143K Hold
23,712
– – ﹤0.01% 3016
2015
Q3 		$186K Hold
23,712
– – ﹤0.01% 2969
2015
Q2 		$146K Buy
+23,712
New +$184K ﹤0.01% 3022

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Charles Schwab's GNMX Position: Q2 2017 in Review

Charles Schwab sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2017, closing a stake of 44,012 shares — an estimated $82K sold.

Charles Schwab first reported a position in GNMX in Q2 2015 and held it in 8 quarters. The position peaked at $246K in Q3 2016. 51 funds tracked by Wall St. Rank hold GNMX as of Q2 2017.

  • Charles Schwab reported no remaining Aevi Genomic Medicine Inc position as of Q2 2017 after selling out during the quarter.
  • Charles Schwab sold 44,012 Aevi Genomic Medicine Inc shares in Q2 2017, an estimated $82K.
  • Charles Schwab first reported a position in Aevi Genomic Medicine Inc in Q2 2015 and held it in 8 quarters.
  • Charles Schwab's Aevi Genomic Medicine Inc position peaked at $246K in Q3 2016.
  • 51 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2017.

Based on Charles Schwab's 13F filing for Q2 2017, filed 2 Aug 2017.